Amgen Inc. $AMGN Stock: Raleigh Capital Management Inc. Trims Holdings

Raleigh Capital Management Inc. decreased its position in Amgen Inc. (NASDAQ:AMGN) by 95.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 164 shares of the medical research company’s stock after selling 3,856 shares during the quarter. Raleigh Capital Management Inc.’s holdings in Amgen were worth $69,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. International Assets Investment Management LLC grew its holdings in shares of Amgen by 1,105.8% during the third quarter. International Assets Investment Management LLC now owns 46,000 shares of the medical research company’s stock worth $19,389,000 after purchasing an additional 42,185 shares during the last quarter. CHICAGO TRUST Co NA boosted its stake in Amgen by 5.7% in the third quarter. CHICAGO TRUST Co NA now owns 3,041 shares of the medical research company’s stock valued at $1,282,000 after acquiring an additional 163 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al grew its stake in shares of Amgen by 6.1% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 85,905 shares of the medical research company’s stock worth $36,210,000 after purchasing an additional 4,920 shares during the period. Partners Wealth Management LLC acquired a new stake in shares of Amgen in the 3rd quarter valued at approximately $328,000. Finally, Soltis Investment Advisors LLC raised its holdings in Amgen by 8.8% in the third quarter. Soltis Investment Advisors LLC now owns 31,750 shares of the medical research company’s stock worth $13,383,000 after purchasing an additional 2,578 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Up 1.1%

Shares of AMGN opened at $466.01 on Friday. The stock has a fifty day moving average of $419.96 and a 200-day moving average of $374.79. Amgen Inc. has a 52 week low of $288.00 and a 52 week high of $475.65. The stock has a market capitalization of $251.94 billion, a price-to-earnings ratio of 28.96, a PEG ratio of 3.41 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The company had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. During the same period in the previous year, the business posted $6.02 earnings per share. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 22.96 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen’s dividend payout ratio (DPR) is 62.65%.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Dividend support: Amgen’s dividend announcement helped reinforce the stock’s income appeal and contributed to its move to a new 1-year high. Amgen Sets New 1-Year High Following Dividend Announcement
• Positive Sentiment: Analyst endorsement: RBC Capital reaffirmed its Buy rating, providing continued Wall Street support ahead of the earnings release. RBC Capital Reaffirms Buy Rating
• Positive Sentiment: Pipeline and rare-disease progress: New Phase 3 dazodalibep data in Sjögren’s disease, UPLIZNA updates and a rare-disease diagnostic collaboration support Amgen’s longer-term growth narrative beyond its established products. Rare Disease Updates
• Neutral Sentiment: Key near-term catalyst: Amgen will report third-quarter 2026 results after the market close on November 3. The current consensus EPS estimate cited in previews is $5.79, making earnings, guidance and management commentary important tests for the recent rally. Amgen Q3 2026 Preview
• Negative Sentiment: Profitability concerns: Management has warned of rising expenses, while MariTide development is consuming substantial cash. Investors are watching whether growth from Repatha and TEZSPIRE can offset higher costs and protect margins. Amgen Faces Rising Expenses Ahead of Q3 Results
• Negative Sentiment: Valuation and execution risk: A skeptical earnings preview highlights concerns about the CFO transition, spending growth and whether Amgen can meet expectations after a substantial year-to-date advance. Amgen Earnings Preview

Analysts Set New Price Targets

Several analysts have commented on the stock. Jefferies Financial Group restated a “hold” rating and set a $410.00 target price on shares of Amgen in a report on Wednesday, September 23rd. Royal Bank Of Canada increased their price objective on shares of Amgen from $400.00 to $430.00 and gave the stock an “outperform” rating in a research note on Thursday, October 8th. Piper Sandler boosted their target price on shares of Amgen from $427.00 to $457.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Weiss Ratings upgraded Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. Finally, Robert W. Baird upped their price target on shares of Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $389.71.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 2,000 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,222 shares of company stock worth $2,540,926 in the last 90 days. Corporate insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.